Results 191 to 200 of about 1,168,068 (349)
Age-related cerebral small vessel disease and inflammaging [PDF]
Tiemei Li +7 more
openalex +1 more source
HUCMSC‐Apo‐mvs enhance peripheral nerve repair by modulating the inflammatory microenvironment (IME), primarily through coordinated actions on three functional cells. They recruit macrophages and promote their polarization from pro‐inflammatory M1 to anti‐inflammatory M2 phenotypes, increasing secretion of IL‐10 and VEGF.
Haolin Liu +21 more
wiley +1 more source
Design of Trials for Cerebral Small Vessel Disease and Vascular Cognitive Impairment. [PDF]
Phan E, Loo SP, Quinn TJ.
europepmc +1 more source
Retinal small vessel pathology is associated with disease burden in multiple sclerosis [PDF]
Rebecca Wicklein +8 more
openalex +1 more source
This manuscript describes the cultivation of viable microvessels from cryopreserved human brain tissue. When embedded in hydrogels and cultured in microfluidic devices, these microvessels exhibit complex architectures reminiscent of arterioles and capillaries, can be perfused, and display intact barrier function. Collectively, these results demonstrate
Brian J. O'Grady +5 more
wiley +1 more source
An iPSC-derived model for drug screening in cerebral small vessel disease. [PDF]
Granata A +5 more
europepmc +1 more source
This work introduces photo‐crosslinkable tyraminated poly(vinyl alcohol)‐gelatin (PVA‐GT) hydrogels as tunable injectable platforms for tissue engineering and growth factor delivery applications. This schematic illustrates the two developed hydrogel formulations and the experimental workflow used to evaluate their physico‐chemical properties in vitro ...
Alessia Longoni +15 more
wiley +1 more source
Cerebral Small Vessel Disease Burden in Acute Ischemic Stroke and the Role of Physical Activity: Cross-Sectional Study. [PDF]
Damsbo AG +11 more
europepmc +1 more source
Peptomer Linkers Enable Kinetic Control over Co‐Delivery of Multiple Chemotherapeutics
A key challenge in combinatorial chemotherapeutic drug delivery is independent control over release kinetics, especially with drugs of similar size and structure. Here, peptoid substitutions to proteolytically degradable peptides enabled the design of fast and slow‐releasing drug linkers.
Carolyn M. Watkins +3 more
wiley +1 more source

